Browsing by Author "0115106"
Now showing items 1-20 of 25
-
A Computer Simulation Model of Pharmaceutical Innovation
(Pharmaceutical Economics: Papers Presented at the 6. Arne Ryde Symposium, Helsingborg, Sweden 1982, 1984) -
A Computer Simulation Model of Pharmaceutical Innovation
(Pharmaceutical Economics, 1984) -
A New Look at the Returns and Risks to Pharmaceutical R&D
(1990-07)This study investigates the returns to R&D for 100 new drugs introduced into the United States during the decade of the 1970s. In contrast to prior studies, it incorporates several significant structural changes that have ... -
An Econometric Model of the Tobacco Industry
(1969)N thi's paper we describe an econometric model of the American tobacco industry for the period 1949 through 1966. The model contains 19 equations and is divided into three major blocks - (1) leaf production, (2) leaf price, ... -
Brand Loyalty, Entry and Price Competition in Pharmaceuticals After the 1984 Drug Act
(Journal of Law and Economics, 1992-10) -
Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act
(1992-10)IN 1984, Congress enacted a new law that greatly affected the economics of the pharmaceutical industry in the United States. It has been characterized as the most important legislation affecting competition in the pharmaceutical ... -
Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry
(1978)INNOVATION in the U.S. ethical drug industry in recent years has been characterized by a number of adverse developments. In particular, there has been a sharp decline in the rate of new product introductions and the incentive ... -
Impact of Public Policy on Drug Innovation and Pricing
(Impact of Public Policy on Drug Innovation and Pricing, 1976) -
Longer Patents for Lower Imitation Barriers: The 1984 Drug Act
(1986)In this paper we analyze its likely impacts on competition in the pharmaceutical industry, the incentives for innovation, and general consumer welfare. -
PIONEERS, IMITATORS, AND GENERICS - A SIMULATION-MODEL OF SCHUMPETERIAN COMPETITION
(QUARTERLY JOURNAL OF ECONOMICS, 1987-08) -
Pressures from the Demand Side: Changing Market Dynamics and Industrial Structure
(Consolidation and Competition in the Pharmaceutical Industry, 2001) -
R&D costs and returns by therapeutic category
(Drug Information Journal, 2004-09-03)Objectives: This study examines the degree to which therapeutic class accounts for variability in drug development costs. It also scrutinizes how sales levels vary across the associated therapeutic classes for those drugs ... -
R&d Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
(International Journal of the Economics of Business, 1995-01-01)This study examines the relationships between firm size, R&D costs and output in the pharmaceutical industry. Project-level data from a survey of 12 US-owned pharmaceutical firms on drug development costs, development phase ... -
Returns on R&D for 1990s New Drug Introductions
(PharmacoEconomics, 2002) -
Returns to R&D on new drug introductions in the 1980s.
(J Health Econ, 1994-12)This study finds that the mean IRR for 1980-84 U.S. new drug introductions is 11.1%, and the mean NPV is 22 million (1990 dollars). The distribution of returns is highly skewed. The results are robust to plausible changes ... -
Structural Effects of Regulation on Innovation in the Ethical Drug Industry
(Essays on industrial organization, in honor of Joe S. Bain, 1976) -
Substitution laws and innovation in the pharmaceutical industry.
(1979)The pharmaceutical industry has been among the most innovative while being one of the most highly regulated industries in the United States. Government regulation of pharmaceutical product quality started in 19061 and has ... -
SUBSTITUTION LAWS AND INNOVATION IN THE PHARMACEUTICAL-INDUSTRY
(LAW AND CONTEMPORARY PROBLEMS, 1979) -
Technical Change and Firm Size: The Pharmaceutical Industry
(1974)The plan of this paper is as follows: First, we summarize and point out several problems we found with Comanor's study. Section III presents the results from a two-equation model that decomposes the technical change measure ...
